Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Florida International University
With
National Institute on Drug Abuse (NIDA)
Low levels of zinc are associated with an increased risk of HIV-related death and opportunistic infections in HIV infected individuals. Drug users are especially susceptible to zinc deficiency. The purpose of this trial is to evaluate the effectiveness of zinc therapy in preventing immune failure in HIV infected individuals who abuse drugs.
This trial will last 30 months. Participants will be randomly assigned to receive either zinc supplements or placebo. Male participants will receive 15 mg of zinc and female participants will receive 12 mg of zinc. Clinical and laboratory study visits will occur at 3 or 6 month intervals throughout the study.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
HIV infected
Drug User
Blood zinc level greater than 0.35 mcg/mL and less than 0.75mcg/ml
You may not be if
Currently participating in an another clinical trial
Blood selenium level less than 85 mcg/L
Pregnant or intends to become pregnant
Clareo Health | Zinc Therapy in HIV Infected Individuals Who Abuse Drugs
